Varicella immunization and herpes zoster

Herpes

Volumn 12, Issue 3, 2005, Pages 59-

  Volpi, Antonio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

CHICKENPOX; EDITORIAL; HEALTH SURVEY; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INCIDENCE; INFECTION RISK; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; T LYMPHOCYTE; VARICELLA ZOSTER VIRUS;

ADULT; AGE DISTRIBUTION; AGED; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CLINICAL TRIALS; HERPES ZOSTER; HUMANS; IMMUNIZATION; INCIDENCE; TREATMENT OUTCOME;

HERPES ZOSTER; HUMAN HERPESVIRUS 3;

EID: 29544450518     PISSN: 09697667     EISSN: 14701537     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Hope-Simpson RE. Epidemiology of shingles. J R Soc Med 1991;84:184.
2. Donahue JG, Choo PW, Manson JE. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-1609.
3. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of post herpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000;321:794-796.
4. Di Luzio Paparatti U, Arpinelli F, Visona G. Herpes zoster and its complications in Italy: an observational survey. J Infect 1999;38:116-119.
5. Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplege A et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001;33:62-69.
6. Volpi A, Gross G, Hercogova J, Johnson RW. Current management of herpes zoster. The European view. Am J Clin Dermatol 2005;6:317-325.
7. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002 360:678-682.
8. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188:1336-1344.
9. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005;191:2002-2007.
10. Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005;5:68.
11. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-2284.
12. Johnson RW. Herpes zoster in the immunocompetent patient: management of post-herpetic neuralgia. Herpes 2003;10:38-45.
13. Gnann JW, Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002;347:340-346.